Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 10, 2021 16:01 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics to Participate in Upcoming Investor Conferences

SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer,...
November 09, 2021 16:01 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Reports Third-Quarter Financial Results, Provides Operational Updates

Updated Preliminary Clinical Data Presented for Lead Drug Candidate Repotrectinib and Elzovantinib at the AACR-NCI-EORTC ConferenceMultiple FDA Interactions Anticipated in Q4 2021 and 1H 2022 for...
November 08, 2021 16:01 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Announces Appointment of Adam Levy as Senior Vice President of Investor Relations

SAN DIEGO, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer,...
November 02, 2021 16:01 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics to Host Third Quarter 2021 Conference Call

SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer,...
October 23, 2021 09:12 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Presents Early Clinical Data for Repotrectinib From Care Study in Pediatric and Young Adult Patients at SIOP 2021 Virtual Congress

Early Clinical Activity and Safety Profile Support Continued Investigation of Repotrectinib in Pediatric Tumors Harboring ALK, ROS1 or NTRK Alterations Repotrectinib Demonstrated Confirmed Responses...
October 13, 2021 16:01 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics and EQRx Announce Clinical Collaboration to Evaluate Elzovantinib in Combination with Aumolertinib in Patients with EGFR Mutant Met-Amplified Advanced Non-Small Cell Lung Cancer

SAN DIEGO, Calif. and CAMBRIDGE, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that...
October 11, 2021 16:05 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics to Present Early Clinical Data for Repotrectinib From the CARE Study in Pediatric and Young Adult Patients at SIOP 2021 Virtual Congress

SAN DIEGO, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer,...
October 08, 2021 08:30 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Presents TRIDENT-1 Study Clinical Data for Repotrectinib in NTRK+ Advanced Solid Tumors in Plenary Session at 2021 AACR-NCI-EORTC Conference

Confirmed Objective Response Rate of 48 Percent in Patients with NTRK+ TKI-Pretreated Advanced Solid TumorsConfirmed Objective Response Rate of 62 Percent in NTRK+ TKI-Pretreated Advanced Solid Tumor...
October 07, 2021 07:00 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Presents Updated Preliminary Clinical Data for Repotrectinib and Elzovantinib (TPX-0022) at 2021 AACR-NCI-EORTC Conference and Provides Regulatory Updates

Repotrectinib Demonstrates Clinical Activity Across Multiple ROS1+ TKI-Pretreated NSCLC Cohorts, with Confirmed Objective Response Rates of 30-39 Percent in TRIDENT-1 StudyRepotrectinib Demonstrates...
October 04, 2021 09:00 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients with NTRK-Positive, TKI-Pretreated Advanced Solid Tumors

SAN DIEGO, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer,...